Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

A genetic variant of the NTCP gene is associated with HBV infection status in a Chinese population

Authors: Jingmin Yang, Yuan Yang, Mingying Xia, Lianghui Wang, Weiping Zhou, Yajun Yang, Yueming Jiang, Hongyang Wang, Ji Qian, Li Jin, Xiaofeng Wang

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

To investigate whether genetic variants of the HBV receptor gene NTCP are associated with HBV infection in the Han Chinese population.

Methods

We sequenced the entire 23 kb NTCP gene from 111 HBeAg-positive HBsAg carriers (PSE group), 110 HBeAg-negative HBsAg carriers (PS group), and 110 control subjects. Then, we performed association analyses of suggestively significant SNPs with HBV infection in 1075 controls, 1936 PSs and 639 PSEs.

Results

In total, 109 rare variants (74 novel) and 38 single nucleotide polymorphisms (SNPs, one novel) were screened. Of the seven non-synonymous rare variants, six were singletons and one was a double hit. All three damaging rare singletons presented exclusively in the PSE group. Of the five SNPs validated in all 3650 subjects, the T allele of rs4646287 was significantly decreased (p = 0.002) in the PS group (10.1 %) and PSE group (8.1 %) compared to the controls (10.9 %) and was decreased to 7.4 % in the PSE hepatocellular carcinoma (HCC) subgroup. Additionally, rs4646287-T was associated with a 0.68-fold (95 % CI = 0.51–0.89, p = 0.006) decreased risk of PSE compared with the controls. The NTCP mRNA level was lower in HCC tissues in “CT + TT” carriers than in “CC” carriers.

Conclusions

We found a genetic variant (rs4646287) located in intron 1 of NTCP that may be associated with increased risk of HBV infection in Han Chinese.
Appendix
Available only for authorised users
Literature
1.
European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85.CrossRef
2.
Sjogren M. Immunization and the decline of viral hepatitis as a cause of acute liver failure. Hepatology. 2003;38(3):554–6.CrossRefPubMed
3.
McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135(9):759–68.CrossRefPubMed
4.
Toh QC, Tan TL, Teo WQ, et al. Identification of cellular membrane proteins interacting with hepatitis B surface antigen using yeast split-ubiquitin system. Int J Med Sci. 2005;2(3):114–7.CrossRefPubMedPubMedCentral
5.
Cho DY, Yang GH, Ryu CJ, Hong HJ. Molecular chaperone GRP78/BiP interacts with the large surface protein of hepatitis B virus in vitro and in vivo. J Virol. 2003;77(4):2784–8.CrossRefPubMedPubMedCentral
6.
Budkowska A, Quan C, Groh F, et al. Hepatitis B virus (HBV) binding factor in human serum: candidate for a soluble form of hepatocyte HBV receptor. J Virol. 1993;67(7):4316–22.PubMedPubMedCentral
7.
Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049.CrossRefPubMedPubMedCentral
8.
Zhong G, Yan H, Wang H, et al. Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes. J Virol. 2013;87:7176.CrossRefPubMedPubMedCentral
9.
Drexler JF, Geipel A, Konig A, et al. Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes. Proc Natl Acad Sci U S A. 2013;110(40):16151–6.CrossRefPubMedPubMedCentral
10.
Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet. 2009;41(5):591–5.CrossRefPubMed
11.
Jiang DK, Sun J, Cao G, et al. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet. 2013;45(1):72–5.CrossRefPubMed
12.
Li S, Qian J, Yang Y, et al. GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet. 2012;8(7):e1002791.CrossRefPubMedPubMedCentral
13.
Zhang H, Zhai Y, Hu Z, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet. 2010;42(9):755–8.CrossRefPubMed
14.
Su Z, Li Y, Liao Y, et al. Association of the gene polymorphisms in sodium taurocholate cotransporting polypeptide with the outcomes of hepatitis B infection in Chinese Han population. Infect Genet Evol. 2014;27:77–82.CrossRefPubMed
15.
Peng L, Zhao Q, Li Q, et al. The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B. Hepatol. 2015;61(4):1251–60.CrossRef
16.
Dai CY, Yu ML, Chen SC, et al. Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan. J Clin Pathol. 2004;57(2):141–5.CrossRefPubMedPubMedCentral
17.
Hasan KN, Rumi MA, Hasanat MA, et al. Chronic carriers of hepatitis B virus in Bangladesh: a comparative analysis of HBV-DNA, HBeAg/anti-HBe, and liver function tests. Southeast Asian J Trop Med Public Health. 2002;33(1):110–7.PubMed
18.
Wang XF, Lu M, Qian J, et al. Rationales, design and recruitment of the Taizhou Longitudinal Study. BMC Public Health. 2009;9:233.CrossRef
19.
Paul E. Cizdziel Domenica Simms, Piotr Chomczynski, TRIzol™: a new reagent for optimal single-step isolation of RNA. Focus. 1993;15(4):99–102.
20.
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–5.CrossRefPubMed
21.
Shiao T, Iwahashi M, Fortune J, et al. Structural and functional characterization of liver cell-specific activity of the human sodium/taurocholate cotransporter. Genomics. 2000;69(2):203–13.CrossRefPubMed
22.
23.
Erdman MM, Creekmore LH, Fox PE, et al. Diagnostic and epidemiologic analysis of the 2008–2010 investigation of a multi-year outbreak of contagious equine metritis in the United States. Prev Vet Med. 2011;101(3–4):219–28.CrossRefPubMed
24.
Ho RH, Leake BF, Roberts RL, Lee W, Kim RB. Ethnicity-dependent polymorphism in Na + −taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem. 2004;279(8):7213–22.CrossRefPubMed
25.
Tokuhiro S, Yamada R, Chang X, et al. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet. 2003;35(4):341–8.CrossRefPubMed
26.
Lio D, Marino V, Serauto A, et al. Genotype frequencies of the +874 T- > A single nucleotide polymorphism in the first intron of the interferon-gamma gene in a sample of Sicilian patients affected by tuberculosis. Eur J Immunogenet. 2002;29(5):371–4.CrossRefPubMed
27.
Rohrer J, Conley ME. Transcriptional regulatory elements within the first intron of Bruton’s tyrosine kinase. Blood. 1998;91(1):214–21.PubMed
28.
29.
Yan H, Peng B, Liu Y, et al. Viral entry of Hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol. 2014;88:3273.CrossRefPubMedPubMedCentral
30.
Ding X, Mizokami M, Yao G, et al. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China. Intervirology. 2001;44(1):43–7.CrossRefPubMed
31.
Zumbika E, Ruan B, Xu CH, et al. HBV genotype characterization and distribution in patients with HBV-related liver diseases in Zhejiang Province, P.R. China: possible association of co-infection with disease prevalence and severity. Hepatobiliary Pancreat Dis Int. 2005;4(4):535–43.PubMed
Metadata
Title
A genetic variant of the NTCP gene is associated with HBV infection status in a Chinese population
Authors
Jingmin Yang
Yuan Yang
Mingying Xia
Lianghui Wang
Weiping Zhou
Yajun Yang
Yueming Jiang
Hongyang Wang
Ji Qian
Li Jin
Xiaofeng Wang
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2257-6

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Oral cancer incidence and survival rates in the Republic of Ireland, 1994-2009

Research article

The role of GAGE cancer/testis antigen in metastasis: the jury is still out

Erratum

Erratum to: Conformational changes and translocation of tissue-transglutaminase to the plasma membranes: role in cancer cell migration

Research article

The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis

Study protocol

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

Research article

Leptin and insulin up-regulate miR-4443 to suppress NCOA1 and TRAF4, and decrease the invasiveness of human colon cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits